Full Press Release Details
Tiziana Life Sciences Highlighted in Forbes
Article entitled "New T Cell Antibody Treatment
Improves Outcomes For Covid Patients" reviews the company's first in class foralumab, a unique Intranasal monoclonal antibody designed
to treat multiple sclerosis and a range of other neurodegenerative diseases
NEW YORK, March 17, 2023 -- Tiziana Life
Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough
immunomodulation therapies via novel routes of drug delivery, today announced that the Company was highlighted in a FORBES article highlighting
foralumab, the Company's unique intranasal monoclonal antibody, which is currently in clinical development to treat multiple sclerosis
and a range of other neurodegenerative diseases. Foralumab is the world's only fully human, anti-CD3 mAb in clinical development.
Forbes contributing author, William A. Haseltine,
highlighted foralumab in his article entitled "New T Cell Antibody Treatment Improves Outcomes for Covid Patients".
Noted in the article was:
"Foralumab induces many factors that
impact improved tissue remodeling, induction of immune cells, and restriction of effector function, improving disease outcomes while fighting
the virus to full strength. These benefits are not limited to Covid-19 patients, as similar results were observed in patients with multiple
"The anti-CD3 monoclonal treatment effectively
modulates the T cell inflammatory response by up or downregulating specific gene and protein expressions, resulting in less severe disease.
This novel avenue should be further explored, as more drugs with similar mechanisms could prevent the deaths of thousands."
full Forbes article, please visit the following link:
Activated T cells play an important role in the
inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor, dampens inflammation
by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets, an effect demonstrated in patients
with COVID and with multiple sclerosis, as well as in healthy normal subjects. Intranasal foralumab Phase 2 trials are expected to start
in Q3 2023 in patients with non-active SPMS. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of inflammatory
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage
biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes
of immunotherapy. Tiziana's innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement
in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's lead candidate, intranasal foralumab,
the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana's
technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad
pipeline applications.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development and Investor Relations
+44 (0) 207 495 2379
LifeSci Advisors, LLC